Your browser does not fully support modern features. Please upgrade for a smoother experience.
Atypical Antipsychotics and Metabolic Syndrome: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Vivi Li and Version 1 by Marco Scarselli.

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia, bipolar disorders and other psychotic disorders. However, they might cause metabolic syndrome (MetS) in terms of weight gain, dyslipidemia, type 2 diabetes (T2D), and high blood pressure, which are responsible for reduced life expectancy and poor adherence. Importantly, there is clear evidence that early metabolic disturbances can precede weight gain, even if the latter still remains the hallmark of AAPs use. In fact, AAPs interfere profoundly with glucose and lipid homeostasis acting mostly on hypothalamus, liver, pancreatic β-cells, adipose tissue, and skeletal muscle. Their actions on hypothalamic centers via dopamine, serotonin, acetylcholine, and histamine receptors affect neuropeptides and 5′AMP-activated protein kinase (AMPK) activity, thus producing a supraphysiological sympathetic outflow augmenting levels of glucagon and hepatic glucose production. In addition, altered insulin secretion, dyslipidemia, fat deposition in the liver and adipose tissues, and insulin resistance become aggravating factors for MetS. In clinical practice, among AAPs, olanzapine and clozapine are associated with the highest risk of MetS, whereas quetiapine, risperidone, asenapine and amisulpride cause moderate alterations. The new AAPs such as ziprasidone, lurasidone and the partial agonist aripiprazole seem more tolerable on the metabolic profile. However, these aspects must be considered together with the differences among AAPs in terms of their efficacy, where clozapine still remains the most effective. Intriguingly, there seems to be a correlation between AAP’s higher clinical efficacy and increase risk of metabolic alterations. Finally, a multidisciplinary approach combining psychoeducation and therapeutic drug monitoring (TDM) is proposed as a first-line strategy to avoid the MetS. In addition, pharmacological treatments are discussed as well.

  • atypical antipsychotics (AAPs)
  • G protein-coupled receptors (GPCRs)
  • metabolic syndrome (MetS)
  • weight gain
  • type 2 diabetes
  • dyslipidemia
  • clozapine
  • olanzapine
Please wait, diff process is still running!

References

  1. De Hert, M.A.; Van Winkel, R.; Van Eyck, D.; Hanssens, L.; Wampers, M.; Scheen, A.; Peuskens, J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 2006, 83, 87–93.
  2. Yevtushenko, O.O.; Cooper, S.J.; O’Neill, R.; Doherty, J.K.; Woodside, J.V.; Reynolds, G.P. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br. J. Psychiatry 2008, 192, 424–428.
  3. Laursen, T.M. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr. Res. 2011, 131, 101–104.
  4. Taipale, H.; Tanskanen, A.; Mehtälä, J.; Vattulainen, P.; Correll, C.U.; Tiihonen, J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020, 19, 61–68.
  5. Tiihonen, J.; Wahlbeck, K.; Lönnqvist, J.; Klaukka, T.; Ioannidis, J.P.A.; Volavka, J.; Haukka, J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. Br. Med. J. 2006, 333, 224–227.
  6. Dickerson, F.B.; Brown, C.H.; Daumit, G.L.; Lijuan, F.; Goldberg, R.W.; Wohlheiter, K.; Dixon, L.B. Health status of individuals with serious mental illness. Schizophr. Bull. 2006, 32, 584–589.
  7. Aringhieri, S.; Carli, M.; Kolachalam, S.; Verdesca, V.; Cini, E.; Rossi, M.; McCormick, P.J.; Corsini, G.U.; Maggio, R.; Scarselli, M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol. Ther. 2018, 192, 20–41.
  8. Huhn, M.; Nikolakopoulou, A.; Schneider-Thoma, J.; Krause, M.; Samara, M.; Peter, N.; Arndt, T.; Bäckers, L.; Rothe, P.; Cipriani, A.; et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019, 394, 939–951.
  9. Kowalchuk, C.; Castellani, L.N.; Chintoh, A.; Remington, G.; Giacca, A.; Hahn, M.K. Antipsychotics and glucose metabolism: How brain and body collide. Am. J. Physiol. Endocrinol. Metab. 2019, 316, E1–E15.
  10. Ballon, J.S.; Pajvani, U.; Freyberg, Z.; Leibel, R.L.; Lieberman, J.A. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol. Metab. 2014, 25, 593–600.
  11. Gründer, G.; Hippius, H.; Carlsson, A. The “atypicality” of antipsychotics: A concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009, 8, 197–202.
  12. Gillespie, A.L.; Samanaite, R.; Mill, J.; Egerton, A.; MacCabe, J.H. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry 2017, 17, 1–14.
  13. Scarselli, M.; Armogida, M.; Chiacchio, S.; DeMontis, M.G.; Colzi, A.; Corsini, G.U.; Maggio, R. Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments. Eur. J. Pharmacol. 2000, 397, 291–296.
  14. Rossi, M.; Fasciani, I.; Marampon, F.; Maggio, R.; Scarselli, M. The first negative allosteric modulator for dopamine D2 and D3 receptors, SB269652 may lead to a new generation of antipsychotic drugs. Mol. Pharmacol. 2017, 91, 586–594.
  15. Maggio, R.; Scarselli, M.; Capannolo, M.; Millan, M.J. Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation. Eur. Neuropsychopharmacol. 2015, 25, 1470–1479.
  16. Fasciani, I.; Petragnano, F.; Aloisi, G.; Marampon, F.; Carli, M.; Scarselli, M.; Maggio, R.; Rossi, M. Allosteric modulators of g protein-coupled dopamine and serotonin receptors: A new class of atypical antipsychotics. Pharmaceuticals 2020, 13, 388.
  17. Meltzer, H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 2013, 64, 393–406.
  18. Seeman, P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin. Ther. Targets 2006, 10, 515–531.
  19. Schmid, C.L.; Streicher, J.M.; Meltzer, H.Y.; Bohn, L.M. Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of akt. Neuropsychopharmacology 2014, 39, 1902–1913.
  20. Fasciani, I.; Pietrantoni, I.; Rossi, M.; Mannoury la Cour, C.; Aloisi, G.; Marampon, F.; Scarselli, M.; Millan, M.J.; Maggio, R. Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors. Eur. J. Pharmacol. 2018, 819, 181–189.
  21. Carli, M.; Kolachalam, S.; Aringhieri, S.; Rossi, M.; Giovannini, L.; Maggio, R.; Scarselli, M. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them? Curr. Neuropharmacol. 2017, 16, 222–230.
  22. Aringhieri, S.; Kolachalam, S.; Gerace, C.; Carli, M.; Verdesca, V.; Brunacci, M.G.; Rossi, C.; Ippolito, C.; Solini, A.; Corsini, G.U.; et al. Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT2A receptor agonism. Eur. Neuropsychopharmacol. 2017, 27, 383–398.
  23. Fu, Z.; Gilbert, E.R.; Liu, D. Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes. Curr. Diabetes Rev. 2012, 9, 25–53.
  24. Tabarean, I.V. Histamine receptor signaling in energy homeostasis. Neuropharmacology 2016, 106, 13–19.
  25. Vehof, J.; Risselada, A.J.; Al Hadithy, A.F.Y.; Burger, H.; Snieder, H.; Wilffert, B.; Arends, J.; Wunderink, L.; Knegtering, H.; Wiersma, D.; et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology 2011, 216, 257–265.
  26. Reynolds, G.P.; Kirk, S.L. Metabolic side effects of antipsychotic drug treatment—Pharmacological mechanisms. Pharmacol. Ther. 2010, 125, 169–179.
  27. Beaulieu, J.M.; Gainetdinov, R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63, 182–217.
  28. Xu, Y.; Jones, J.E.; Lauzon, D.A.; Anderson, J.G.; Balthasar, N.; Heisler, L.K.; Zinn, A.R.; Lowell, B.B.; Elmquist, J.K. A serotonin and melanocortin circuit mediates D-fenfluramine anorexia. J. Neurosci. 2010, 30, 14630–14634.
  29. Lam, D.D.; Garfield, A.S.; Marston, O.J.; Shaw, J.; Heisler, L.K. Brain serotonin system in the coordination of food intake and body weight. Pharmacol. Biochem. Behav. 2010, 97, 84–91.
  30. Zhou, L.; Sutton, G.M.; Rochford, J.J.; Semple, R.K.; Lam, D.D.; Oksanen, L.J.J.; Thornton-Jones, Z.D.; Clifton, P.G.; Yueh, C.Y.; Evans, M.L.; et al. Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways. Cell Metab. 2007, 6, 398–405.
  31. Bickerdike, M. 5-HT2C Receptor Agonists as Potential Drugs for the Treatment of Obesity. Curr. Top. Med. Chem. 2005, 3, 885–897.
  32. Fernø, J.; Varela, L.; Skrede, S.; Vázquez, M.J.; Nogueiras, R.; Diéguez, C.; Vidal-Puig, A.; Steen, V.M.; López, M. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 2011, 6.
  33. Vatamaniuk, M.Z.; Horyn, O.V.; Vatamaniuk, O.K.; Doliba, N.M. Acetylcholine affects rat liver metabolism via type 3 muscarinic receptors in hepatocytes. Life Sci. 2003, 72, 1871–1882.
  34. Breier, A.; Wolkowitz, O.M.; Roy, A.; Potter, W.Z.; Pickar, D. Plasma norepinephrine in chronic schizophrenia. Am. J. Psychiatry 1990, 147, 1467–1470.
  35. Savoy, Y.E.; Ashton, M.A.; Miller, M.W.; Nedza, F.M.; Spracklin, D.K.; Hawthorn, M.H.; Rollema, H.; Matos, F.F.; Hajos-Korcsok, E. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: Evidence for the involvement of sympathetic regulation. Schizophr. Bull. 2010, 36, 410–418.
  36. Lian, J.; Huang, X.F.; Pai, N.; Deng, C. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways. Psychoneuroendocrinology 2014, 48, 77–86.
  37. Steinberg, G.R.; Kemp, B.E. AMPK in health and disease. Physiol. Rev. 2009, 89, 1025–1078.
  38. Kim, S.F.; Huang, A.S.; Snowman, A.M.; Teuscher, C.; Snyder, S.H. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. USA 2007, 104, 3456–3459.
  39. Han, H.S.; Kang, G.; Kim, J.S.; Choi, B.H.; Koo, S.H. Regulation of glucose metabolism from a liver-centric perspective. Exp. Mol. Med. 2016, 48, 1–10.
  40. Smith, G.C.; Chaussade, C.; Vickers, M.; Jensen, J.; Shepherd, P.R. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 2008, 51, 2309–2317.
  41. Budick-Harmelin, N.; Anavi, S.; Madar, Z.; Tirosh, O. Fatty acids-stress attenuates gluconeogenesis induction and glucose production in primary hepatocytes. Lipids Health Dis. 2012, 11, 1–11.
  42. BONACCORSI, A.; GARATTINI, S.; JORI, A. Studies on the Hyperglycaemia Induced By Chlorpromazine in Rats. Br. J. Pharmacol. Chemother. 1964, 23, 93–100.
  43. Manu, P.; Correll, C.U.; Wampers, M.; van Winkel, R.; Yu, W.; Shiffeldrim, D.; Kane, J.M.; De Hert, M. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr. Res. 2013, 143, 358–362.
  44. Houseknecht, K.L.; Robertson, A.S.; Zavadoski, W.; Gibbs, E.M.; Johnson, D.E.; Rollema, H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: Implications for adverse metabolic effects. Neuropsychopharmacology 2007, 32, 289–297.
  45. Oh, K.J.; Park, J.; Lee, S.Y.; Hwang, I.; Kim, J.B.; Park, T.S.; Lee, H.J.; Koo, S.H. Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 2011, 300, 624–632.
  46. Xu, H.; Zhuang, X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: A critical review. Neuropsychiatr. Dis. Treat. 2019, 15, 2087–2099.
  47. Cai, H.L.; Tan, Q.Y.; Jiang, P.; Dang, R.L.; Xue, Y.; Tang, M.M.; Xu, P.; Deng, Y.; Li, H.D.; Yao, J.K. A potential mechanism underlying atypical antipsychotics-induced lipid disturbances. Transl. Psychiatry 2015, 5.
  48. Siafis, S.; Tzachanis, D.; Samara, M.; Papazisis, G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr. Neuropharmacol. 2017, 16, 1210–1223.
  49. Melkersson, K.; Khan, A.; Hilding, A.; Hulting, A.L. Different effects of antipsychotic drugs on insulin release in vitro. Eur. Neuropsychopharmacol. 2001, 11, 327–332.
  50. Melkersson, K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur. Neuropsychopharmacol. 2004, 14, 115–119.
  51. Sussman, K.E.; Pollard, H.B.; Leitner, J.W.; Nesher, R.; Adler, J.; Cerasi, E. Differential control of insulin secretion and somatostatin-receptor recruitment in isolated pancreatic islets. Biochem. J. 1983, 214, 225–230.
  52. Rubi, B.; Ljubicic, S.; Pournourmohammadi, S.; Carobbio, S.; Armanet, M.; Bartley, C.; Maechler, P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J. Biol. Chem. 2005, 280, 36824–36832.
  53. Zhang, Q.; Zhu, Y.; Zhou, W.; Gao, L.; Yuan, L.; Han, X. Serotonin Receptor 2C and Insulin Secretion. PLoS ONE 2013, 8.
  54. Teff, K.L.; Rickels, M.R.; Grudziak, J.; Fuller, C.; Nguyen, H.L.; Rickels, K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013, 62, 3232–3240.
  55. Rickels, M.R.; Perez, E.M.; Peleckis, A.J.; Alshehabi, E.; Nguyen, H.L.; Stefanovski, D.; Rickels, K.; Teff, K.L. Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia. Am. J. Physiol. Endocrinol. Metab. 2018, 315, E250–E257.
  56. Weston-Green, K.; Huang, X.F.; Deng, C. Second generation antipsychotic-induced type 2 diabetes: A role for the muscarinic M3 receptor. CNS Drugs 2013, 27, 1069–1080.
  57. Nagata, M.; Yokooji, T.; Nakai, T.; Miura, Y.; Tomita, T.; Taogoshi, T.; Sugimoto, Y.; Matsuo, H. Blockade of multiple monoamines receptors reduce insulin secretion from pancreatic β-cells. Sci. Rep. 2019, 9, 1–10.
  58. Gonçalves, P.; Araújo, J.R.; Martel, F. Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms. Eur. Neuropsychopharmacol. 2015, 25, 1–16.
  59. Vestri, H.S.; Maianu, L.; Moellering, D.R.; Garvey, W.T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: Effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32, 765–772.
  60. Rojo, L.E.; Gaspar, P.A.; Silva, H.; Risco, L.; Arena, P.; Cubillos-Robles, K.; Jara, B. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol. Res. 2015, 101, 74–85.
  61. Albaugh, V.L.; Singareddy, R.; Mauger, D.; Lynch, C.J. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS ONE 2011, 6.
  62. Nicol, G.E.; Yingling, M.D.; Flavin, K.S.; Schweiger, J.A.; Patterson, B.W.; Schechtman, K.B.; Newcomer, J.W. Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths a randomized clinical trial. JAMA Psychiatry 2018, 75, 788–796.
  63. Pillinger, T.; McCutcheon, R.A.; Vano, L.; Mizuno, Y.; Arumuham, A.; Hindley, G.; Beck, K.; Natesan, S.; Efthimiou, O.; Cipriani, A.; et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet Psychiatry 2020, 7, 64–77.
  64. Jassim, G.; Skrede, S.; Vázquez, M.J.; Wergedal, H.; Vik-Mo, A.O.; Lunder, N.; Diéguez, C.; Vidal-Puig, A.; Berge, R.K.; López, M.; et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology 2012, 219, 783–794.
  65. Gao, Z.; Zhang, X.; Zuberi, A.; Hwang, D.; Quon, M.J.; Lefevre, M.; Ye, J. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol. Endocrinol. 2004, 18, 2024–2034.
  66. Schenk, S.; Saberi, M.; Olefsky, J.M. Insulin sensitivity: Modulation by nutrients and inflammation. J. Clin. Investig. 2008, 118, 2992–3002.
  67. Hemmrich, K.; Gummersbach, C.; Pallua, N.; Luckhaus, C.; Fehsel, K. Clozapine enhances differentiation of adipocyte progenitor cells. Mol. Psychiatry 2006, 11, 980–981.
  68. Barateiro, A.; Mahú, I.; Domingos, A.I. Leptin resistance and the neuro-adipose connection. Front. Endocrinol. 2017, 8, 8–11.
  69. Frühbeck, G.; Catalán, V.; Rodríguez, A.; Ramírez, B.; Becerril, S.; Salvador, J.; Portincasa, P.; Colina, I.; Gómez-Ambrosi, J. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci. Rep. 2017, 7, 1–8.
  70. Grajales, D.; Ferreira, V.; Valverde, Á.M. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain. Cells 2019, 8, 1336.
  71. Ren, L.; Zhou, X.; Huang, X.; Wang, C.; Li, Y. The IRS/PI3K/Akt signaling pathway mediates olanzapine-induced hepatic insulin resistance in male rats. Life Sci. 2019, 217, 229–236.
  72. Burghardt, K.J.; Ward, K.M.; Sanders, E.J.; Howlett, B.H.; Seyoum, B.; Yi, Z. Atypical antipsychotics and the human skeletal muscle lipidome. Metabolites 2018, 8, 64.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback